40th week of 2014 patent applcation highlights part 56 |
Patent application number | Title | Published |
20140295429 | BIOSAMPLE STORAGE DEVICES AND METHODS OF USE THEREOF - The present invention provides sample collection, shipping, and storage devices and methods of using the same. These devices and methods are useful, for example, for collecting, shipping, and storing biological samples, such as blood, serum, buccal samples, tissue homogenates, or cell lysates in a dry state. The devices and methods facilitate the rapid drying of biological samples collected on the devices, thereby improving the quality of the stored sample, particularly the protein and small molecule components of the stored sample. The present invention further provides methods of recovering biological samples from such devices. | 2014-10-02 |
20140295430 | METHOD FOR ANALYZING BIOMOLECULES AND BIOMOLECULE ANALYZER - The method for analyzing biomolecules, includes the steps of: immobilizing biomolecules to be analyzed on surfaces of magnetic microparticles; reacting labeled probe molecules with the biomolecules to be analyzed; collecting and immobilizing the microparticles on a support substrate; and measuring a label on the support substrate. Since single-molecule immobilized magnetic microparticles are used in the present invention, the number of biomolecules can be counted, and since hybridization and an antigen-antibody reaction are performed with the microparticles having biomolecules immobilized thereon dispersed, the reaction can be rapidly performed. Further, the type and the abundance of biomolecules of interest can be determined at a single molecular level, so as to evaluate, in particular, the absolute concentration of biomolecules. | 2014-10-02 |
20140295431 | METHOD OF ALLELE-SPECIFIC AMPLIFICATION - A method of selectively producing and amplifying a cDNA sequence of a target allele of a gene, wherein the target allele is a mutant allele or is a specific allele of a polymorphic gene, the method comprising: (a) providing a sample comprising an mRNA transcript of the target allele; (b) performing a reverse-transcription reaction to generate a cDNA sequence from the mRNA transcript, and (c) amplifying the cDNA of the target allele; wherein the reverse-transcription reaction is selective for reverse transcription of the mRNA transcript of the target allele over an mRNA transcript of an alternative allele of the same gene. | 2014-10-02 |
20140295432 | PARTICLE REPULSION TO ENHANCE SURFACE CONTACT IN MAGNETIC PARTICLE IMMUNOASSAYS - The present invention relates to a device for detecting a target molecule within a sample comprising a sample container for the measurement of the target molecule within a sample, a magnetic particle, wherein said particle is functionalized with a first binding molecule capable of specifically binding to said target molecule, wherein said first binding molecule is attached to the particle, and a repulsive surface structure, which is directly attached to the surface of said particle, wherein said repulsive surface structure covers the surface of the magnetic particle so as to result in a specific net charge and/or steric repulsion of the magnetic particle, and a sensor surface comprising a second binding molecule, wherein said magnetic particles are capable of binding said second binding molecule of the sensor surface directly or indirectly; wherein the number of bound particles is directly or inversely related to the amount of target molecules present in the sample; and wherein said repulsive surface structure conveys an electrostatic and/or steric pushing effect on said magnetic particles towards said sensor surface. In a second aspect the invention describes a device for detecting a target molecule within a sample comprising a mixture of at least two types of magnetic particles, wherein one type is functionalized with a first binding molecule capable of specifically binding to said target molecule, wherein said first binding molecule is attached to the particle, and a second type is functionalized with a repulsive surface structure, which is directly attached to the surface of said particle, wherein said repulsive surface structure covers the surface of the magnetic particle so as to result in a specific net charge of the magnetic particle, and a sensor surface comprising a second binding molecule, wherein said magnetic particles are capable of binding said second binding molecule of the sensor surface directly or indirectly. Furthermore, the invention describes a method of detecting the presence or amount of a target molecule within a sample, as well as the use of a magnetic particle for detecting a target molecule within a sample. | 2014-10-02 |
20140295433 | Method of Detection Using Nano Carbon Carrier Modified by Ionizing Radiation - A detection method for cancer is provided. Magnetic carbon beads are used. The carbon beads are highly specified to a cancer. Surface area of grafted antigen are broadened by grafting functional molecules. Number of antigen is increased on the surface. Thus, the present invention improves sensitivity and accuracy of disease detection and greatly saves cost. The present invention can be applied for sample purification or massive disease detection. | 2014-10-02 |
20140295434 | DETECTION METHOD OF MICRO-RNA WITH HIGH SPECIFICITY - The invention provides a method for detecting miRNA based on polymerase chain reaction comprising EvaGreen dye, and the use of EvaGreen dye in elevating the binding specificity of primers to templates in PCR. | 2014-10-02 |
20140295435 | METHOD FOR DETECTING BACILLUS ANTHRACIS - A method for detecting | 2014-10-02 |
20140295436 | Methods for Multiplexing Recombinase Polymerase Amplification - This disclosure provides for methods and reagents for rapid multiplex RPA reactions and improved methods for detection of multiplex RPA reaction products. In addition, the disclosure provides new methods for eliminating carryover contamination between RPA processes. | 2014-10-02 |
20140295437 | Cyanine compounds and their application as quenching compounds - The present invention provides methods and non-fluorescent carbocyanine quencher compounds having the general formula: | 2014-10-02 |
20140295438 | METHOD AND COMPONENTS FOR DETECTING NUCLEIC ACID CHAINS - The invention relates to a novel method for the enzymatic marking of nucleic acid chains (target sequences) by means of nucleotide conjugates. Said nucleotide conjugates are able, under reaction conditions, to specifically bind to the target sequence and integrate into the complementary growing strand by means of a polymerase. The nucleic acid chains marked by such conjugates can be bound to the solid phase. The marking can be carried out parallel to the enzymatic amplification of target sequences. | 2014-10-02 |
20140295439 | Nucleic Acid Amplification - Methods and compositions for the amplification of nucleic acids are disclosed. Amplification methods provided herein may be performed under isothermal conditions. Methods and compositions may include reagents such as restriction enzymes, polymerases, ligases, primers, and polynucleotide adaptors. | 2014-10-02 |
20140295440 | Nucleic Acid Amplification - Methods and compositions for the amplification of nucleic acids and generation of concatemers are disclosed. Amplification methods provided herein may be performed under isothermal conditions. Methods and compositions may include reagents such nucleic acid polymerases and primers. | 2014-10-02 |
20140295441 | CARTRIDGE INTERFACE MODULE - A cartridge interface module (CIM), configured to engage with a removable microfluidic cartridge in a nucleic acid analyzer system can include a fluidics component, which is configured to initiate and support a liquid extraction of nucleic acids from a biological sample contained in the removable microfluidic cartridge. The CIM also includes a polymerase chain reaction (PCR) assembly component which can be configured to initiate and support amplification of the extracted nucleic acids. The CIM may also include a high voltage electrodes component that is configured to initiate and support separation of the amplified nucleic acids into nucleic acid fragments in a separation channel of the removable microfluidic cartridge. The CIM also includes a detection optics component that can be configured to collect, detect, and direct label nucleic acid fragments. The CIM is configured to integrate with a microfluidic chip architecture of an inserted removable microfluidic cartridge. | 2014-10-02 |
20140295442 | MODULATION OF MICROGLIA ACTIVATION - The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation. | 2014-10-02 |
20140295443 | POLYNUCLEOTIDE SEQUENCES OF CANDIDA DUBLINIENSIS AND PROBES FOR DETECTION - The present invention relates to identification of centromeric sequences of | 2014-10-02 |
20140295444 | DIAGNOSIS AND TREATMENT OF BREAST CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies. | 2014-10-02 |
20140295445 | Method for the Carry-Over Protection in DNA Amplification Systems Targeting Methylation Analysis Achieved by a Modified Pre-Treatment of Nucleic Acids - Particular aspects provide methods for specific amplification of template DNA in the presence of potentially contaminating PCR products from previous amplification experiments. Particular embodiments comprise, in a first step, contacting DNA with a bisulfite solution, which sulfonates unmethylated (but not methylated) cytosines, resulting in cytosine deamination and generation of sulfonated uracil. Such sulfonation protects the template nucleic acid from being a target for the enzyme uracil-DNA-glycosylase (UNG), whereas any contaminating DNA, which contains unprotected unsulfonated or desulfonated uracils, is degraded enzymatically while the UNG is active. After UNG treatment and inactivation thereof, the sulfonated uracil bases are converted into uracil by desulfonation. Such aspects have substantial utility for decontamination of nucleic acid samples; e.g., for avoiding amplification of ‘carry over products’ in the context of DNA methylation analysis. In further aspects, the inventive methods can be generally used as simplified methods of bisulfite treatment. | 2014-10-02 |
20140295446 | METHODS, COMPOSITIONS, AND KITS FOR RARE ALLELE DETECTION - Methods and kits are provided for nucleic acid analysis. In an illustrative method, Snapback-ARMS primers are used to amplify preferentially a target nucleic acid that is present in a low allele fraction. In another embodiment, tailed primers are used to identify the preferentially amplified allele. | 2014-10-02 |
20140295447 | PRIMER SET, METHOD FOR AMPLIFYING TARGET NUCLEIC ACID SEQUENCE USING SAME, AND METHOD FOR DETECTING MUTATED NUCLEIC ACID USING SAME - The present invention provides a primer set including primers that can be designed easily, with which an amplification distance can be shortened. Provided is a primer set for use in a method for isothermally amplifying a target nucleic acid sequence 4. The primer set includes a first primer 1F and a second primer 1R. The first primer 1F includes, on the 3′ side thereof, a sequence (A′) that can hybridize to a sequence (A) on the 3′ side of the target nucleic acid sequence. The second primer 1R includes, on the 3′ side thereof, a sequence (B′) that can hybridize to a sequence (B) on the 3′ side of either a strand extended from the first primer or a complementary strand of the target nucleic acid sequence 4. The first primer 1F and the second primer 1R include, on the 5′ sides thereof, sequences (C) that are substantially identical to each other. | 2014-10-02 |
20140295448 | SUPPRESSION OF TLA2-CpFTSY GENE EXPRESSION FOR IMPROVED SOLAR ENERGY CONVERSION EFFICIENCY AND PHOTOSYNTHETIC PRODUCTIVITY IN ALGAE - The invention provides method and compositions to minimize the chlorophyll antenna size of photosynthesis by decreasing TLA2 gene expression, thereby improving solar conversion efficiencies and photosynthetic productivity in green microalgae, under bright sunlight conditions. | 2014-10-02 |
20140295449 | SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS - The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject. | 2014-10-02 |
20140295450 | CELL ANALYZING METHOD AND CELL ANALYZER - The present invention provides a method for analyzing a cell. The method comprises steps of: regulating a temperature of a medium to a predetermined degree, wherein the cell is preserved in the medium; and obtaining an optical information by irradiating light on the cell. | 2014-10-02 |
20140295451 | METHOD, COMPOSITION AND KIT OF VISUALISATION AND CHARACTERIZATION OF THE NERVOUS SYSTEM BY COMBINING THE STAINING FOR METAL IMPREGNATION AND IMMUNOHISTOCHEMISTRY - A method of visualization and characterization of the nervous system, which combines two techniques for tissue staining, mercuric impregnation and immunohistochemistry, is described. The method disclosed makes compatible one with the other procedures of staining by carrying them out on tissues subjected to adequate fixing procedures. Thus, the method makes feasible to combine morphometric analysis, which can typically be carried out with mercuric impregnation, with antigenic and/or neurochemical cellular characterization, which can typically be obtained with immunohistochemistry. The method has proven simple, reliable, and suitable for both conventional microscopy and confocal laser scanning microscopy. | 2014-10-02 |
20140295452 | ANTI-CMET ANTIBODY AND ITS USE FOR THE DETECTION AND THE DIAGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to a novel antibody capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for this antibody. The invention likewise comprises the use of said antibody, and corresponding processes, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibody for the prognosis or diagnostic of certain cancers. | 2014-10-02 |
20140295453 | SAMPLE ANALYZER, SAMPLE ANALYSIS METHOD, AND NON-TRANSITORY STORAGE MEDIUM - To provide a sample analyzer capable of accurately obtaining the number of analyzable samples. When analyzing a sample collected from a subject, a CPU of the sample analyzer calculates the number of analyzable samples based on a remaining number of tests of a reagent set in a reagent holding section and the number of tests of the reagent to be consumed in measurement of a control, and causes a output section to display the number of analyzable samples. When creating a calibration curve, the CPU calculates the number of analyzable samples based on a remaining number of tests of the reagent set in the reagent holding section, the number of tests of the reagent to be consumed in measurement of the control, and the number of tests of the reagent to be consumed in measurement of a calibrator, and causes the output section to display the number of analyzable samples. | 2014-10-02 |
20140295454 | VARIANTS OF VEGFR AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF PREGNANCY ASSOCIATED MEDICAL CONDITIONS - An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed. | 2014-10-02 |
20140295455 | ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER - The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-β1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1. | 2014-10-02 |
20140295456 | RENAL CELL CARCINOMA BIOMARKERS - Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker. | 2014-10-02 |
20140295457 | GENE CLUSTER FOR BIOSYNTHESIS OF GRISELIMYCIN AND METHYLGRISELIMYCIN - The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents. | 2014-10-02 |
20140295458 | METHOD OF REVERSIBLY STAINING A TARGET CELL - The present invention relates to methods of reversibly staining a target cell. The invention also relates to methods of isolating a target cell or a target cell population that is defined by the presence of at least one common specific receptor molecule. The invention also provides kits that can be used to carry out the methods of the invention. | 2014-10-02 |
20140295459 | MARKERS FOR IDENTIFYING TUMOR CELLS, METHODS AND KIT THEREOF - The present disclosure relates to a combination of biological markers for identification of prognosis of cancer. The present disclosure further relates to a method of identifying the said markers, a method of predicting prognosis and a method of planning personalized treatment for cancer. The present disclosure further relates to a kit/test comprising the antibodies against/other methods of detecting said markers for the said prediction. | 2014-10-02 |
20140295460 | Analyte Detection Using Magnetic Hall Effect - Determining a presence of a target analyte in a fluid sample includes mixing multiple magnetic particles with the fluid sample, in which the magnetic particles are each bound to one or more binding moieties that specifically bind to the target analyte, flowing the fluid sample containing the magnetic particles through a fluidic channel, exposing the fluid sample in the fluidic channel to a magnetic field, measuring a signal from a Hall effect sensor while the fluid sample flows through the fluidic channel, and determining whether the target analyte is present in the fluid sample when the measured signal is in a first range of values. | 2014-10-02 |
20140295461 | Method for Determining Lung Injury Using Desmosine and Isodesmosine as Biomarkers - The subject invention is directed to a method for biochemically determining the extent of emphysematous changes in the lung. This method is entirely novel in that it links a biochemical parameter (the ratio of free to peptide-bound desmosine and isodesmosine [DID]) to specific morphological changes in lung tissue consisting of airspace enlargement and rupture of alveolar walls. While the total amount of DID in blood, urine, and sputum have been previously used to measure the rate of breakdown of lung elastic fibers, recent insights using percolation theory, have shown that the ratio of free to peptide-bound DID specifically reflects the total amount of elastic fiber damage in the lung, and is therefore a sensitive measure of emphysematous changes in the lung (which are the direct result of elastic fiber breakdown in alveolar septa). Furthermore, this new method establishes a relatively narrow range of values for normal individuals (without lung disease), which has not been previously possible by measuring total levels of DID (due to their large variability). The technique may be used to determine the amount of pulmonary emphysema in patients with chronic obstructive lung disease, and may also serve as a screening test for healthy smokers and other asymptomatic individuals (e.g. those with alpha-1 antitrypsin deficiency) who are at risk for developing pulmonary emphysema. Early detection of lung elastic fiber injury will result in more timely therapeutic intervention to slow the progression of the disease. | 2014-10-02 |
20140295462 | RBM3 Protein in Colorectal Cancer Prognostics - The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and | 2014-10-02 |
20140295463 | ELISA Detection of Urine DEK to Predict and Diagnose Bladder Cancer in Humans - The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans. | 2014-10-02 |
20140295464 | Detection of Degradation Products of Feline NT-proBNP - A method for determining the amount of NT-proBNP in blood samples from felines. The method includes detecting degradation products of feline NT-proBNP by various methods, including using antibodies, kits and devices. | 2014-10-02 |
20140295465 | USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN - This disclosure relates to the use of anti-α-synuclein antibody to diagnose an elevated level of α-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels of α-synuclein in a blood plasma or CSF following administration to the test subject of an anti-α-synuclein antibody or antigen-binding fragment thereof, which can bind α-synuclein with sufficient activity to alter the net efflux of α-synuclein from brain to blood, or from brain to CSF. | 2014-10-02 |
20140295466 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 2014-10-02 |
20140295467 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 2014-10-02 |
20140295468 | TEST SUBSTANCE ASSAY METHOD, TEST SUBSTANCE ASSAY KIT, AND TEST SUBSTANCE ASSAY REAGENT - The test substance assay method includes (i) obtaining a mixed solution by mixing (a) first dry particles that are modified with first binding substances exhibiting binding properties specific to a test substance, have an average particle size of 100 nm to 200 nm, and have labels, and (b) second dry particles that are modified with second binding substances not exhibiting binding properties specific to the test substance, have an average particle size of 100 nm to 200 nm, and do not have labels with (c) a test sample solution containing the test substance; (ii) applying the mixed solution onto a substrate; (iii) causing the test substance to be trapped in a reaction site on the substrate that has third binding substances having binding properties specific to the test substance or has substances exhibiting binding properties to the first binding substances; and (iv) detecting the test substance. | 2014-10-02 |
20140295469 | In Vitro Assessment of Cardiovascular Events by Assay for Neo-Eptitopes of Titin Protein - A bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a titin protein by a proteinase comprises contacting a sample with an antibody specifically binding said neo-epitope and determining the level of binding. Partial sequences of titin that may be detected include: | 2014-10-02 |
20140295470 | METHOD AND REAGENT KIT FOR MEASURING ACTIVATED PARTIAL THROMBOPLASTIN TIME - The present invention provides a method for measuring activated partial thromboplastin time. The method comprises: a first mixing step of mixing a blood plasma with a first reagent, wherein the first reagent comprises an activator and phosphatidylglycerol at a concentration equal to or greater than 25 μg/mL; a second mixing step of mixing a sample obtained in the first mixing step with a second reagent comprising a calcium salt; and a step of measuring coagulation time of the sample obtained in the second mixing step. | 2014-10-02 |
20140295471 | DETERMINATION OF THE THROMBOGENIC POWER OF HUMAN IMMUNOGLOBULINS - A kit for the determination of the thrombogenic power of human immunoglobulins contained in a biologically acceptable product. Also a process making it possible to determine the thrombogenic power linked to the presence of activated Factor XI and/or activated Factor IX and/or activated Factor XII, and/or activated Factor VII and/or activated Factor X in a sample capable of being administered to humans. | 2014-10-02 |
20140295472 | Paper Based Diagnostic Test - A device utilizing agglutination and its method of use to diagnose diseases or conditions. The diagnostic device may comprise a substrate having pores, an agglutination zone, and a test readout zone wherein said agglutination zone is functionalized with an agglutinating agent to cause agglutination of the sample. | 2014-10-02 |
20140295473 | METHOD AND TEST MIXTURES FOR DETECTING THE PRESENCE OR ABSENCE OF TARGET MICROBES IN A TEST SAMPLE - A method of and test mixture for detecting the presence or absence of a target microbe in a sample is provided. The method includes the steps of: a) providing a test mixture that includes micro particles, a substrate in an amount that is sufficient to support log phase growth of the target microbe until a detectable characteristic signal is produced in the test mixture and sample admixture, and an amount of vitamin, amino acid, element and salt ingredients; b) combining the powdered test mixture and sample to form the admixture; and c) detecting the presence or absence of target microbes in the sample based on the presence or absence of the detectable characteristic. | 2014-10-02 |
20140295474 | METHOD FOR DISSOLUTION TESTING OF SOLID COMPOSITIONS CONTAINING DIGESTIVE ENZYMES - The invention is directed to a process for measuring the amount of digestive enzymes released from a solid composition in a dissolution medium by fluorescence spectroscopy. The invention is also directed to a combined method for measuring both the dissolution and gastroresistance of a solid compositions comprising pancrelipase. | 2014-10-02 |
20140295475 | ENZYME COCKTAILS PREPARED FROM MIXED CULTURES - The application provides methods of producing a mixture of enzymes using two or more cell lines, methods of identifying or constructing cell lines for producing a mixture of enzymes, and methods of preparing a cell bank for producing a mixture of enzymes. | 2014-10-02 |
20140295476 | GLUTAMATE OXIDASE MUTAGENESIS FOR DIAGNOSTIC TESTING - The described invention provides a method of generating a catalytically active oxidase enzyme preparation. The described invention also provides a means of generating reagents for a protease detection sensor which can use colorimetric, fluorescent, or electrochemical detection. Further, the invention describes a system for a protease detecting sensor. | 2014-10-02 |
20140295477 | Kit For Sampling And Detection Of Endotoxin In Aqueous Solution - The present invention relates to a simple, rapid, and cost-effective test kit for detecting bacterial endotoxin in aqueous solutions, such as water for dialysis or dialysate, using an endotoxin-activatable clotting agent-based gel clot assay which can be applied at ambient temperature. The present invention also relates to a method of detecting endotoxin in aqueous solution with use of the test kit. | 2014-10-02 |
20140295478 | BACTERIAL SURROGATE FOR TESTING OF ANTIMALARIALS: thyA KNOCKOUT AND folA KNOCKOUT BACTERIA FOR TESTING OF INHIBITION OF MALARIAL DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYNTHASE - The objective of this invention is to create a double thyA folA knockout | 2014-10-02 |
20140295479 | FLUID PROCESSING AND CONTROL - A fluid control and processing system for controlling fluid flow among a plurality of chambers comprises a body including a fluid processing region continuously coupled fluidicly with a fluid displacement region. The fluid displacement region is depressurizable to draw fluid into the fluid displacement region and pressurizable to expel fluid from the fluid displacement region. The body includes at least one external port. The fluid processing region is fluidicly coupled with the at least one external port. The fluid displacement region is fluidicly coupled with at least one external port of the body. The body is adjustable with respect to the plurality of chambers to place the at least one external port selectively in fluidic communication with the plurality of chambers. One or more of the chambers may be a processing chamber which includes two ports configured to selectively engage the at least one external port of the body, and a fluid processing material such as an enrichment material or a depletion material. In some embodiments, one or more chambers may include a separation channel, and an electric field may be applied across the separation channel. | 2014-10-02 |
20140295480 | METAL SULFIDE AND RARE-EARTH PHOSPHATE NANOSTRUCTURES AND METHODS OF MAKING SAME - The present invention provides a method of producing a crystalline metal sulfide nanostructure. The metal is a transitional metal or a Group IV metal. In the method, a porous membrane is placed between a metal precursor solution and a sulfur precursor solution. The metal cations of the metal precursor solution and sulfur ions of the sulfur precursor solution react, thereby producing a crystalline metal sulfide nanostructure. | 2014-10-02 |
20140295481 | METHOD FOR SCREENING A DRUG IN RETINAL TISSUE - The subject matter disclosed herein pertains to a method for screening drugs using second-harmonic generation microscopy. The tissue is scanned with a pulsed laser light which has an excitation wavelength. At least some of microtubules within the tissue produce generated light with a second-harmonic wavelength that is half the excitation wavelength. A microtubule pattern within the tissue is determined based on an analysis of the generated second-harmonic wavelength. | 2014-10-02 |
20140295482 | Media Compositions for Promoting Bacterial and Fungal Growth - Methods and compositions for enhancing or promoting germination of bacterial spores, and yeasts are disclosed herein. The composition of the present invention comprises an extract obtained from banana or any member belonging to the genus | 2014-10-02 |
20140295483 | APPARATUS AND METHOD FOR IN-VITRO DRUG SCREENING FOR CANCER METASTASIS - The present invention includes an apparatus and methods for detecting cancer cell metastasis, the apparatus comprising: a multi-well plate for growing cells in tissue culture; one or more shafts, cones, or fins that fit within one or more of the wells of the multi-well plate and that can be positioned in close proximity to the bottom of the one or more wells; a rotational motor connected to drive the one or more shafts, cones, or fins to rotate, such that rotation of the shafts, cones, or fins creates fluid flow within the one or more wells; and a detector capable of measuring cells within the wells. | 2014-10-02 |
20140295484 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY - The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides the necessary information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through one or more metabolic pathways of interest. By this method, a comparison between subjects and control subjects reveals the effects of the chemical entity or entities on the biomarkers. This, in turn, allows for the identification of potential therapeutic uses or toxicities of the compound. Combinations of compounds can also be systematically evaluated for complementary, synergistic, or antagonistic actions on the metabolic pathways of interest, using the methods of the present invention as a strategy for identifying and confirming novel therapeutic or toxic combinations of compounds. | 2014-10-02 |
20140295485 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY - The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides the necessary information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through one or more metabolic pathways of interest. By this method, a comparison between subjects and control subjects reveals the effects of the chemical entity or entities on the biomarkers. This, in turn, allows for the identification of potential therapeutic uses or toxicities of the compound. Combinations of compounds can also be systematically evaluated for complementary, synergistic, or antagonistic actions on the metabolic pathways of interest, using the methods of the present invention as a strategy for identifying and confirming novel therapeutic or toxic combinations of compounds. | 2014-10-02 |
20140295486 | BIOLOGICAL DETECTOR AND METHOD - A biological detector includes a conduit for receiving a fluid containing one or more magnetic nanoparticle-labeled, biological objects to be detected and one or more permanent magnets or electromagnet for establishing a low magnetic field in which the conduit is disposed. A microcoil is disposed proximate the conduit for energization at a frequency that permits detection by NMR spectroscopy of whether the one or more magnetically-labeled biological objects is/are present in the fluid. | 2014-10-02 |
20140295487 | BLOOD CELL ANALYZER AND BLOOD CELL ANALYZING METHOD - A blood cell analyzer comprises a flow cell configured to flow a measurement specimen containing blood cells, a first light source configured to emit light having a first wavelength, a second light source configured to emit light having a second wavelength different from the first wavelength, a first light receiving portion configured to receive first scattered light obtained by irradiating the blood cells passing through the flow cell with light from the first light source, a second light receiving portion configured to receive second scattered light obtained by irradiating the blood cells passing through the flow cell with light from the second light source, and a control section configured to discriminate at least red blood cells from the blood cells contained in the measurement specimen based on detection signals output from the first light receiving portion and the second light receiving portion, respectively. | 2014-10-02 |
20140295488 | BLOOD CELL ANALYZER AND BLOOD CELL ANALYZING METHOD - A blood cell analyzer comprising a flow cell configured to flow a measurement specimen containing blood cells, a first light source configured to emit light having a first wavelength, a second light source configured to emit light having a second wavelength different from the first wavelength, a first light receiving portion configured to receive first scattered light generated by irradiating the blood cells in the measurement specimen with light from the first light source, a second light receiving portion configured to receive second scattered light generated by irradiating the blood cells in the measurement specimen with light from the second light source, and a control section configured to classify at least white blood cells from the blood cells contained in the measurement specimen, based on a detection signal output from the first light receiving portion and a detection signal output from the second light receiving portion. | 2014-10-02 |
20140295489 | ORGANIC COMPOUNDS - The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake. | 2014-10-02 |
20140295490 | FETAL RED BLOOD CELL DETECTION - A device for analyzing a maternal blood sample for quantification of the percentage of fetal red blood cells present with respect to the number of maternal red blood cells includes reagents for mixing with the biological sample, a microfluidic chip, 5 fluid reservoirs, a pumping system, an image acquisition system, an image analysis system, and an electronic control board. The microfluidic channel can confine the objects of interest to a monolayer, and may trap them in an organized array for analysis. The device uses a reduced sample volume and microfluidic pumping and imaging techniques throughout. The disclosed invention holds distinct advantages over the current state of the art in fetal red blood cell quantification in a maternal blood sample by producing faster results, removing operator error, reducing 10 costs, and providing overall simplification of the testing and analysis procedure. | 2014-10-02 |
20140295491 | Duckweed Hydrolysate and use Thereof - A duckweed hydrolysate is provided. A method for producing carotenoids comprising the incubation of microorganisms with the duckweed is also provided. | 2014-10-02 |
20140295492 | Methods for Cell-Free Protein Synthesis - Cell-free protein synthesis systems and methods of using the same for producing in vitro protein materials in high yield are disclosed. The cell-free protein synthesis platform includes (a) a | 2014-10-02 |
20140295493 | Polypeptides Having Protease Activity and Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 2014-10-02 |
20140295494 | HIGH AFFINITY, ANTI-HUMAN IgE ANTIBODIES - The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 2014-10-02 |
20140295495 | Methods of Preventing and Removing Trisulfide Bonds - The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein. | 2014-10-02 |
20140295496 | RECOMBINANT BACULOVIRUS AND USE THEREOF - The present invention provides a recombinant baculovirus. The baculovirus has a genome into which a gene encoding γ-glutamyl carboxylase (GGCX) and a gene encoding DT-diaphorase (NQO1) are incorporated. | 2014-10-02 |
20140295497 | VECTORS AND HOST CELLS COMPRISING A MODIFIED SV40 PROMOTER FOR PROTEIN EXPRESSION - The present disclosure is directed to expression vectors, comprising a weakened SV40 promoter, and recombinant mammalian cells capable of producing high levels of a polypeptide of interest, methods of generating and using such recombinant mammalian cells. | 2014-10-02 |
20140295498 | Targeted Rolling Circle Amplification - Methods for amplifying a desired target region of a nucleic acid through rolling circle amplification with a strand-displacing polymerase are provided. Concatameric hairpin products are resolved with endonuclease digestion, and the resulting amplified product hairpins or fragments can be circularized and employed as templates in a subsequent round of amplification. The methods are effective for targeted amplification of even highly repetitive sequences. Compositions, kits, and systems related to or useful in the methods are also described. | 2014-10-02 |
20140295499 | DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION - Disclosed are mutant DNA polymerases having increased 3′-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases. | 2014-10-02 |
20140295500 | DNA POLYMERASES WITH IMPROVED ACTIVITY - Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases. | 2014-10-02 |
20140295501 | NOVEL METHOD TO LOAD A MAMMALIAN ARTIFICIAL CHROMOSOME WITH MULTIPLE GENES - The invention provides for a system for uploading genes of interest into an artificial chromosome expression system (ACE) that has been engineered to include multiple sites for site-specific, recombination directed integration, whereby a second or further gene of interest can be loaded onto the ACE by a targeting vector, through the acceptor recombination site(s) on said ACE. | 2014-10-02 |
20140295502 | cDNA Synthesis Improvements - The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention. | 2014-10-02 |
20140295503 | METHODS AND DEVICES FOR BIOLOGICAL SAMPLE PREPARATION - Various aspects and embodiments of the present disclosure relate to methods of obtaining and manipulating nucleic acids from samples. In some embodiments, the samples are known to comprise or are suspected of comprising microorganisms such as bacteria and the methods of the invention are used to identify such microorganisms. | 2014-10-02 |
20140295504 | FUNGAL CELLS AND FERMENTATION PROCESSES - The present invention provides an isolated fungal cell that is capable of producing one or more biomass-degrading enzymes and that exhibits increased or decreased expression or copy number of a polynucleotide encoding a PtaB-like protein. Also provided is a fermentation processes for producing one or more biomass-degrading enzymes comprising a fungal cells exhibiting increased or decreased expression or copy number of a polynucleotide encoding a PtaB-like protein. The biomass-degrading enzymes produced by the isolate fungal cell and fermentation processes of the present invention may be used in a process to produce soluble sugars from biomass. | 2014-10-02 |
20140295505 | PROCESS FOR THE RECOVERY OF BETAINE FROM MOLASSES - A process for the recovery of betaine from a raw material consisting essentially of molasses. The process includes a demineralisation step, a conversion step and a separation step. In the demineralisation step the overall amount of salts in the molasses is brought to a level lying below 2 wt. % (on overall dry matter). In the conversion step the molasses is subjected to the action of a fructan-forming enzyme, to form a fructan-containing molasses (fructan-molasses). Finally in the separation step, the fructan-molasses is subjected to a chromatographic separation, thereby obtaining a betaine-containing fraction. Whereby the demineralisation step is executed prior to the separation step and whereby demineralisation step may be executed prior to, during, or subsequent to the conversion step. The raw material may alternatively contain or consist essentially of thick juice. | 2014-10-02 |
20140295506 | METHOD TO PRODUCE HYDRAZIDE - A method to produce hydrazide from triacylglycerol, the method includes steps of mixing vegetable oil with an organic solvent in a reactor forming a mixture, adding hydrazinemonohydrate into the mixture, stirring the mixture, adding catalyst, stirring the mixture to form hydrazide and separating the hydrazide from the mixture. Most illustrative drawing: | 2014-10-02 |
20140295507 | METHOD FOR PRODUCING BIODEGRADABLE POLYMER AND BIOMASS FUEL CONVERTED FROM CARBON SOURCE BY RECOMBINANT MICROORGANISMS - Disclosed is a method for producing biodegradable polymer and ethanol converted from carbon source by using recombinant microorganisms, comprising the steps of: (A) providing recombinant microorganisms transformed with plasmids containing at least a gene encoding for glycerol utilizing enzyme and a gene encoding for polyhydroxyalkanoate synthase; (B) culturing the recombinant microorganisms in a medium containing glycerol; (C) inducing expression of the genes of step (A), thereby obtaining polyhydroxyalkanoate and ethanol; and (D) recovering the polyhydroxyalkanoate and the ethanol; wherein the recombinant microorganisms have a glycerol utilization rate more than 90% (w/w), and have polyhydroxyalkanoate accumulated therein to a biomass content thereof at least 30% (w/w). | 2014-10-02 |
20140295508 | METHODS FOR PREPARING 2,5-FURANDICARBOXYLIC ACID - Provided are methods of producing 2,5-furandicarboxylic acid (FDCA) from renewable sources such as seaweed, alginate, oligoalginate, pectin, oligopectin, polygalacturonate, galacturonate, and/or oligogalacturonate. The sugars in the renewable sources can be converted into one or more intermediates such as 4-deoxy-L-erythro-5-hexoseulose uronate (DEHU), 4-deoxy-L-threo-5-hexosulose uronate (DTHU), 5-hydroxymethyl furfural (HMF), 2,5-dihydroxymethyl furan (DHMF), and 5-formyl-2-furancarboxylic acid (FFA), which can be converted into FDCA by dehydration and cyclization to produce 5-formyl-2-furancarboxylic acid (FFA), followed by oxidation to produce FDCA. DEHU or DTHU may also be converted into FDCA by oxidation to produce 2,3-dihydroxy-5-oxohexanedioic acid (DOHA), which then undergoes dehydration and cyclization to produce FDCA. | 2014-10-02 |
20140295509 | Pre-Treatment of Cellulosic Material - A method of pre-treating a cellulosic material before hydrolysis is provided. The method comprises the steps of: impregnating the cellulosic material with a reactive water-soluble gas, such as sulphur dioxide (SO | 2014-10-02 |
20140295510 | Eukaryotic cell and method for producing glycolic acid - The present invention concerns a eukaryotic host selected from microorganisms, and a method for producing glycolic acid using said eukaryotic host cells, especially cells of a genetically modified fungal host. Further this invention relates to a glycolic acid product obtained using the method described here and the use of genetically modified microorganism cells in production of glycolic acid. | 2014-10-02 |
20140295511 | ORGANISMS FOR THE PRODUCTION OF 1,3-BUTANEDIOL - A non-naturally occurring microbial organism includes a microbial organism having a 1,3-butanediol (1,3-BDO) pathway having at least one exogenous nucleic acid encoding a 1,3-BDO pathway enzyme expressed in a sufficient amount to produce 1,3-BDO. The pathway includes an enzyme selected from a 2-amino-4-ketopentanoate (AKP) thiolase, an AKP dehydrogenase, a 2-amino-4-hydroxypentanoate aminotransferase, a 2-amino-4-hydroxypentanoate oxidoreductase (deaminating), a 2-oxo-4-hydroxypentanoate decarboxylase, a 3-hydroxybutyraldehyde reductase, an AKP aminotransferase, an AKP oxidoreductase (deaminating), a 2,4-dioxopentanoate decarboxylase, a 3-oxobutyraldehyde reductase (ketone reducing), a 3-oxobutyraldehyde reductase (aldehyde reducing), a 4-hydroxy-2-butanone reductase, an AKP decarboxylase, a 4-aminobutan-2-one aminotransferase, a 4-aminobutan-2-one oxidoreductase (deaminating), a 4-aminobutan-2-one ammonia-lyase, a butenone hydratase, an AKP ammonia-lyase, an acetylacrylate decarboxylase, an acetoacetyl-CoA reductase (CoA-dependent, aldehyde forming), an acetoacetyl-CoA reductase (CoA-dependent, alcohol forming), an acetoacetyl-CoA reductase (ketone reducing), a 3-hydroxybutyryl-CoA reductase (aldehyde forming), a 3-hydroxybutyryl-CoA reductase (alcohol forming), a 4-hydroxybutyryl-CoA dehydratase, and a crotonase. A method for producing 1,3-BDO, includes culturing such microbial organisms under conditions and for a sufficient period of time to produce 1,3-BDO. | 2014-10-02 |
20140295512 | Ketol-Acid Reductoisomerases With Improved Performance Properties - The present invention relates to recombinant microorganisms comprising at least one nucleic acid molecule encoding a ketol-acid reductoisomerase (KARI) or modified NADH-dependent variant thereof, wherein said KARI is at least about 60% identical to SEQ ID NO: 2. In various aspects of the invention, the recombinant microorganisms may comprise an isobutanol producing metabolic pathway and can be used in methods of making isobutanol. | 2014-10-02 |
20140295513 | High-Performance Ketol-Acid Reductoisomerases - The present invention relates to recombinant microorganisms comprising at least one nucleic acid molecule encoding a ketol-acid reductoisomerase (KARI) or a modified NADH-dependent variant thereof, wherein said KARI is at least about 80% identical to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 28, SEQ ID NO: 40, or SEQ ID NO: 58. The present invention also relates to recombinant microorganisms comprising at least one nucleic acid molecule encoding a ketol-acid reductoisomerase (KARI) or a modified NADH-dependent variant thereof, wherein said KARI is at least about 99% identical to SEQ ID NO: 64. In various aspects of the invention, the recombinant microorganisms may comprise an isobutanol producing metabolic pathway and can be used in methods of making isobutanol. | 2014-10-02 |
20140295514 | FERMENTATIVE GLYCEROL-FREE ETHANOL PRODUCTION - The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD | 2014-10-02 |
20140295515 | CRUDE GLYCEROL FERMENTING PROCESS FOR THE PRODUCTION OF ETHANOL AND HYDROGEN - The present invention concerns a fermenting process of crude glycerol derived from biodiesel production for preparation of ethanol and hydrogen using activated sludge enriched and directly acclimatized on biodiesel by-product | 2014-10-02 |
20140295516 | Genetically Modified Strain of S. Cerevisiae Engineered to Ferment Xylose and Arabinose - The present invention provides a microorganism capable of fermenting arabmose to a desired product such as ethanol. In some embodiments, the organism is also capable of fermenting xylose. In some embodiments, the organism is capable of fermenting arabinose and xylose, and expresses one or more cellulases. | 2014-10-02 |
20140295517 | Host Cells and Constructs Useful for Producing Pinene - The present invention provides for a modified host cell comprising a heterologous pinene synthase (PS), or enzymatically active fragment or variant thereof, and optionally a geranyl pyrophosphate synthase (GPPS), or enzymatically active fragment or variant thereof, or a fusion protein comprising: (a) a PS and (b) a GPPS linked by a linker. | 2014-10-02 |
20140295518 | PROCESS FOR GENERATION OF HYDROGEN AND SYNGAS - The present invention is related to a process for generation of hydrogen and syngas based on biomimetic carbonation and photocatalysis. A path breaking way has been developed for generation of solar fuels in specific hydrogen by coupling biomimetic carbonation with photocatalysis. Efforts are being made worldwide to mimic the reaction for fixation of anthropogenic CO2 into calcium carbonate using carbonic anhydrase (CA) as a biocatalyst. CA is being employed to accelerate the rate of hydration of CO2 to form carbonate ions and proton. Presently carbonate is being precipitated from aqueous solution as calcium carbonate given a suitable saturation of calcium and carbonate ions by addition of appropriate buffer. A major breakthrough in the area of generation of solar fuels like hydrogen has been achieved by coupling biomimetic carbonation with photocatalysis. This approach may prove to be a revolutionary technical advancement required for hydrogen economy demanding carbon neutral hydrogen production. Also the production of hydrogen in addition to carbonates as end products during biomimetic carbonation may make the process commercially viable to be adopted by industries emitting carbon dioxide. The carbonate rich stream has been photocatalytically reduced to formaldehyde. This breakthrough thus opens new horizons in the area of carbon sequestration by virtue of the fact that end product of carbon sequestration is not only environmentally benign product of calcite but it would lead to the generation of clean energy including hydrogen, methane and methanol. Maximum hydrogen evolution has been observed up to 101.14 μmoles/mg of, free CA, 156.8 μmoles/mg of immobilised CA and 101.14 μmoles/mg of CA 6684.5 μmoles/mg of stabilised CA using TiO2/Zn/Pt as photocatalyst. The problem of using Zn as a metal donor has been overcome by illuminating the system. Hydrogen evolution to the tune of 84 μmoles/mg of CA has been observed for system with Zn as metal donor in the presence of Pt as co-catalyst with illumination. | 2014-10-02 |
20140295519 | Thermococcus mutant having improved hydrogen production from formate and methods of hydrogen production by using thereof - The present invention relates to a | 2014-10-02 |
20140295520 | ENGINEERED SUBCELLULAR COMPARTMENTS - This disclosure describes a cell that includes an engineered subcellular compartment that generally includes a proteinaceous shell that includes at least one bacterial microcompartment (BMC) polypeptide. In some embodiments, the engineered subcellular compartment can further include one or more targeted enzymes. We further describe methods of making and using such cells. | 2014-10-02 |
20140295521 | METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN - A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal. | 2014-10-02 |
20140295522 | STORAGE-STABLE LIQUID DETERGENT OR CLEANING AGENT CONTAINING PROTEASE AND AMYLASE - The intention is to improve storage stability in a liquid washing or cleaning agent which contains a protease and amylase. This is achieved by using a protease which comprises an amino acid sequence which, over the entire length thereof, is at least 70% identical to the amino acid sequence stated in SEQ ID no. 1 and, in the numbering according to SEQ ID no. 1, has the amino acid substitution R99E or R99D in combination with at least two further amino acid substitutions which are selected from the group consisting of S3T, V4I and V199I. | 2014-10-02 |
20140295523 | Glucanases, Nucleic Acids Encoding Them and Methods for Making and Using Them - The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability, including thermotolerance or thermostability, at increased or decreased pHs and temperatures. | 2014-10-02 |
20140295524 | PROCESS FOR THE CONTINUOUS PRODUCTION OF CELLULASES BY A FILAMENTOUS FUNGUS USING A CARBON SUBSTRATE OBTAINED FROM AN ACID PRETREATMENT - A process for the production of cellulases and hemicellulases using a strain of a filamentous fungus in a stirred and aerated bioreactor, in at least two phases, a phase a) for growth of said strain in the presence of at least one carbonaceous growth substrate in a closed reactor, a phase b) for the continuous production of cellulases, in which at least one carbonaceous inducer substrate is supplied at a supply rate which is constant over a period of at least more than 200 h, said carbonaceous substrate being at least one aqueous hemicellulosic hydrolysate solution obtained from an acid pre-treatment of a lignocellulosic substrate, said aqueous hemicellulosic hydrolysate solution not undergoing prior sterilization and not undergoing pH rectification, being operated at a dilution rate in the range 0.001 to 0.02 h | 2014-10-02 |
20140295525 | METHOD FOR PRODUCING CELLULASE AND APPARATUS FOR SAID METHOD - A method of producing cellulase includes steps (1) to (3): (1) subjecting an aqueous solution of cellulase derived from filamentaous fungi to filtration through an ultrafiltration membrane with a molecular weight cut off of 100,000 to 200,000 to obtain a filtrate and concurrently obtain a concentrated enzyme liquid as a retentate; (2) further subjecting the filtrate obtained in step (1) to filtration through a second ultrafiltration membrane with a molecular weight cut off of 5,000 to 50,000 to obtain a second concentrated enzyme liquid as a retentate; and (3) mixing the concentrated enzyme liquid obtained in steps (1) and (2) to obtain cellulase derived from filamentaous fungi. | 2014-10-02 |
20140295526 | MODIFIED PROTEASES - This invention relates to modified polynucleotides encoding modified proteases, and methods for altering the production of proteases in microorganisms. In particular, the present invention relates to methods for altering the expression of proteases in microorganisms, such as | 2014-10-02 |
20140295527 | COMPOSITIONS AND METHODS COMPRISING A SUBTILISIN VARIANT - The present invention provides a | 2014-10-02 |
20140295528 | NOVELPOLYPEPTIDES AND BACTERIOPHAGES SPECIFIC TO KLEBSIELLA PNEUMONIAE CAPSULAR TYPE STRAINS - The present invention relates to novel bacteriophages specific to | 2014-10-02 |